Brief: Lipocine Inc - On June 24, 2022, Antares Informed Co Of Its Decision Not To Exercise Their Option To License Tlando XR
29/06/2022 22:52
June 29 (Reuters) - Lipocine Inc LPCN.O :
* LIPOCINE INC - ON JUNE 24, 2022, ANTARES INFORMED CO OF
ITS
DECISION NOT TO EXERCISE THEIR OPTION TO LICENSE TLANDO XR
Further company coverage: LPCN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy